In a report published Tuesday, RBC Capital Markets analyst Brandon Henry downgraded Baxter International, Inc. BAX to Sector Perform from Outperform, keeping its $73.00 price target.
According to the report, it is expected that longer-acting products are to be a "game changer" for
the Hemophilia A space as ~64% of patients said they would eventually switch to a longer-acting recombinant factor VIII product.
“Approximately 82% of hemophilia A patients were aware of longer-acting rFVIII products in development. However, ~58% have not yet discussed these products with their hematologist, as patients see their hematologist on average ~2 times annually. Nonetheless, we expect longer-acting products to be a "game changer" for the hemophilia A space as ~64% of patients said they would eventually switch to a longer-acting rFVIII product (~32% of patients were still "unsure”).”
Some potential risks to BAX include not garnering FDA approval for longer-acting pegylated rFVIII product, longer-term market share losses could be much greater than expected (3,000bp+).
BAX closed Monday at $69.33.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in